BIAS
NKTR icon

Beacon Investment Advisory Services’s Nektar Therapeutics NKTR Stock Holding History

Beacon Investment Advisory Services’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-527
Closed -$281K – 236
2019
Q2 		$281K Sell
527
-1
-0.2% -$501 0.03% 192
2019
Q1 		$266K Sell
528
-1
-0.2% -$593 0.03% 200
2018
Q4 		$261K Buy
+529
New +$319K 0.03% 222

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Beacon Investment Advisory Services's NKTR Position: Q3 2019 in Review

Beacon Investment Advisory Services sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 527 shares — an estimated $281K sold.

Beacon Investment Advisory Services first reported a position in NKTR in Q4 2018 and held it in 3 quarters. The position peaked at $281K in Q2 2019. 288 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • Beacon Investment Advisory Services reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Beacon Investment Advisory Services sold 527 Nektar Therapeutics shares in Q3 2019, an estimated $281K.
  • Beacon Investment Advisory Services first reported a position in Nektar Therapeutics in Q4 2018 and held it in 3 quarters.
  • Beacon Investment Advisory Services's Nektar Therapeutics position peaked at $281K in Q2 2019.
  • 288 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on Beacon Investment Advisory Services's 13F filing for Q3 2019, filed 29 Oct 2019.